Every year, nearly 16,000 children in the United States are diagnosed with cancer.  While the overall survival rate has improved over the past few decades, cancer remains the second leading cause of death in children behind only accidents. And for those who survive, life is often complicated and compromised by life-long, chronic health challenges including heart disease, stunted growth, infertility, secondary cancers, and premature death.

At CURE, we are working fervently to drive forward research which will result in better treatments and cures for childhood cancers. Our goal is to save lives – and entire lifetimes. To this end, we focus our funding on research which is likely to get to the bedside within five years.

Over the past ten years, we have invested nearly $25 million in innovative research which has resulted in important discoveries and treatment options. We are committed to advancing precision medicine as a promising new individualized, gene-based approach to treatment, investing $4.5 million to launch the Precision Medicine Program at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta and more than $600,000 in the Target Pediatric AML project, designated as today’s “highest potential, greatest need AML research effort.”

Additionally, CURE invests nearly $4 million annually in specific research efforts at top pediatric institutions nationwide. Our goal is clear: to reach the day when every child with cancer can be successfully treated.